The Phase III study GLOW (NCT03653507) investigated the efficacy of zolbetuximab in combination with CAPOX as a first-line treatment for patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic GC and GEJ. The gene discussed is ERBB2; the disease is gastric cancer.